Clinical trial
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic…
NCT00472693 · Abramson Cancer Center at Penn Medicine, Other · Completed
Key facts
| NCT number | NCT00472693 |
|---|---|
| Title | Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer |
| Official title | A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer |
| Lead sponsor | Abramson Cancer Center at Penn Medicine, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Abraxane |
| Enrollment | 5 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | May 14, 2007 |
| Last update posted | Apr 9, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: